Seroquel SR NDA Submitted For Schizophrenia
This article was originally published in The Pink Sheet Daily
Executive Summary
AstraZeneca's once-daily sustained-release formula extends the franchise's patent protection until 2017.
You may also be interested in...
AstraZeneca’s Seroquel Gets FDA Nod For Bipolar Depression
Seroquel is the first drug approved for both depressive and manic episodes associated with bipolar disorder, the firm says.
AstraZeneca’s Seroquel Gets FDA Nod For Bipolar Depression
Seroquel is the first drug approved for both depressive and manic episodes associated with bipolar disorder, the firm says.
FDA Cancels Advisory Committee Meeting On J&J’s Paliperidone ER
The company is currently conducting head-to-head trials against AstraZeneca’s antipsychotic Seroquel.